This company listing is no longer active
Akero Therapeutics (1AKRO) Stock Overview
Engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1AKRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Akero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.24 |
| 52 Week High | US$47.02 |
| 52 Week Low | US$44.76 |
| Beta | -0.40 |
| 1 Month Change | 6.24% |
| 3 Month Change | 31.73% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1AKRO | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 0.5% | -1.6% | 1.9% |
| 1Y | n/a | 20.6% | 24.4% |
Return vs Industry: Insufficient data to determine how 1AKRO performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1AKRO performed against the Italian Market.
Price Volatility
| 1AKRO volatility | |
|---|---|
| 1AKRO Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.2% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: 1AKRO's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1AKRO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 75 | Andrew Cheng | akerotx.com |
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Akero Therapeutics, Inc. Fundamentals Summary
| 1AKRO fundamental statistics | |
|---|---|
| Market cap | €3.86b |
| Earnings (TTM) | -€251.91m |
| Revenue (TTM) | n/a |
Is 1AKRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AKRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$292.82m |
| Earnings | -US$292.82m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1AKRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 21:59 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akero Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |
| Citi Research | Citigroup Inc |